These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37348414)

  • 21. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
    J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
    Blomme S; De Paepe P; Devos H; Emmerechts J; Snauwaert S; Cauwelier B
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23211. PubMed ID: 37897298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
    Liang X; Wang J; Bai W; Sun R
    Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):559-64. PubMed ID: 26705179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.
    Han YB; Yang JM; Kwon HJ; Lee JO; Lee JS; Paik JH
    Anticancer Res; 2021 Nov; 41(11):5677-5692. PubMed ID: 34732441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
    Wang XJ; L Jeffrey Medeiros ; Bueso-Ramos CE; Tang G; Wang S; Oki Y; Desai P; Khoury JD; Miranda RN; Tang Z; Reddy N; Li S
    Mod Pathol; 2017 Feb; 30(2):194-203. PubMed ID: 27739436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical features and prognosis of 166 cases of MYC/BCL2 double-expression diffuse large B-cell lymphoma].
    Tang SH; Tian L; Zhao W; Wang J; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):771-777. PubMed ID: 36709172
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
    Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
    Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
    Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
    Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological differences in MYC and BCL2 protein expression between primary extranodal and nodal diffuse large B-cell lymphoma.
    Sasaki Y; Murai S; Hayashi H; Kawamata N; Nagao K; Kuroiwa K; Narita H; Okamura R; Shimada S; Watanuki M; Arai N; Kawaguchi Y; Yanagisawa K; Shiozawa E; Yamochi T; Hattori N
    Pathol Res Pract; 2024 Aug; 260():155425. PubMed ID: 38964118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic and genetic features of the starry-sky pattern in double-expressor diffuse large B-cell lymphoma.
    Sung HJ; Kim D; Yoon DH; Cho H; Huh J; Suh CW; Go H
    Hum Pathol; 2023 Sep; 139():106-116. PubMed ID: 37517597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.